Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Blood (2023) 142 (Supplement 1): 208.

https://doi.org/10.1182/blood-2023-177564

Published: 2023

Journal Articles

Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial

Roberto Mina, MD, Alessandra Larocca, Massimo Offidani, Vanessa Innao, Claudia Cellini, Monica Galli, Giusy Cetani, Mariella Grasso, Giovannino Ciccone, Andrea Capra, Sara Aquino, Claudia Priola, Gloria Margiotta Casaluci, Giovanni De Sabbata, Stelvio Ballanti, Michele Cavo, Mario Boccadoro, Sara Bringhen, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136292

Published: 2020

Journal Articles

Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-137060

Published: 2020

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Blood (2019) 134 (Supplement_1): 3195.

https://doi.org/10.1182/blood-2019-124388

Published: 2019

Journal Articles

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Blood (2017) 130 (Supplement 1): 4541.

https://doi.org/10.1182/blood.V130.Suppl_1.4541.4541

Published: 2017

Journal Articles

Haploidentical Allogeneic Hemopoietic Stem Cell Transplant for High Risk Myelodysplastic Syndrome

Anna Maria Raiola, MD, Sara Aquino, MD, Germana Beltrami, MD, Stefania Bregante, MD, Fabio Cruciani, MD, Carmen Di Grazia, MD, Alida Dominietto, MD, Anna Ghiso, MD, Francesca Gualandi, MD, Adalberto Ibatici, MD, Teresa Lamparelli, MD, Carlo Marani, MD, Maria Teresa van Lint, MD, Riccardo Varaldo, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2016) 128 (22): 3173.

https://doi.org/10.1182/blood.V128.22.3173.3173

Published: 2016

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

Journal Articles

Combined overexpression of WT1 and BAALC genes May Predict AML evolution in MDS Patients

Daniele Avenoso, MD, Enrico De Astis, MD, Nicoletta Colombo, Raffaella Grasso, PhD, Micaela Bergamaschi, MD, Paola Minetto, MD, Sara Aquino, PHD, Davide Lovera, MD, Fabio Cruciani, MD, Fabio Guolo, MD, Filippo Ballerini, PHD, Marino Clavio, MD, Letizia Canepa, MD, Ivana Pierri, MD, Carlo Marani, MD, Marco Gobbi, MD, Maurizio Miglino, PHD

Blood (2013) 122 (21): 5204.

https://doi.org/10.1182/blood.V122.21.5204.5204

Published: 2013

Journal Articles

High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy.

Nicoletta Colombo, Raffaella Grasso, Maurizio Miglino, Marino Clavio, Gianmatteo Pica, MD, Germana Beltrami, Micaela Bergamaschi, Carlo Marani, Antonia Cagnetta, Anna Ghiso, Laura Mitscheunig, Ivana Pierri, Filippo Ballerini, Letizia Canepa, Sara Aquino, Enrico De Astis, Angelo Michele Carella, Marco Gobbi

Blood (2009) 114 (22): 4675.

https://doi.org/10.1182/blood.V114.22.4675.4675

Published: 2009

Journal Articles

Evidence for Killing of Mesenchymal Stem Cells (MSC) by Autologous Natural Killer Lymphocytes.

Alessandro Poggi, MD, PhD, Anna-Maria Massaro, PhD, Simone Negrini, MD, Ivana Pierri, MD, Manuela Balocco, MD, Gianluca Michelis, MD, Sara Aquino, MD, Alessandra Albarello, MD, Marco Gobbi, MD, Maria Raffaella Zocchi, MD

Blood (2004) 104 (11): 1290.

https://doi.org/10.1182/blood.V104.11.1290.1290

Published: 2004

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial

Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Haploidentical Allogeneic Hemopoietic Stem Cell Transplant for High Risk Myelodysplastic Syndrome

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Combined overexpression of WT1 and BAALC genes May Predict AML evolution in MDS Patients

High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy.

Evidence for Killing of Mesenchymal Stem Cells (MSC) by Autologous Natural Killer Lymphocytes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only